Topical testosterone therapy for middle-aged and older men with hypogonadism and either pre-existing or at a high-risk of cardiovascular disease, does increase the risk of adverse cardiac events ...
Testosterone Gel 1.62% CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: primary hypogonadism (congenital or ...
DUBLIN, Oct. 15, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced the launch of an AB-rated generic version of Androgel ® Topical Gel, 1.62% (20.25mg testosterone/1.25g ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback